Literature DB >> 6974819

Induction of bone resorption by parathyroid hormone in congenital malignant osteopetrosis.

F H Glorieux, J M Pettifor, P J Marie, E E Delvin, R Travers, N Shepard.   

Abstract

A male patient, afflicted with malignant congenital osteopetrosis, was studied over a 5 year period. Hypocalcemia (less than 8 mg/dl) with lack of an appropriate increase in serum immunoreactive parathyroid hormone (iPTH) prevailed at all times. Under a calcium restricted diet, a 6-hour infusion of parathyroid extract normalized serum calcium, and increased the urinary hydroxyproline excretion suggesting that bone resorption had been induced. A second attempt to induce resorption was made by infusing a synthetic amino terminal fragment of bovine PTH over a period of 3 weeks at the dose of 1.5 units/kg/hr. This infusion evoked an increase in serum calcium (8.1 to 10.5 mg/dl), urinary calcium (0.03 to 0.65 mg/g creatinine) and urinary hydroxyproline (160 to 372 mg/g creatinine); and urinary hydroxyproline (160 to 372 mg/g creatinine); increases which were reversed by calcitonin administration. Iliac crest bone biopsies were obtained before and on the last day of the 3-week infusion. Quantitative comparison of the two specimens showed that, during PTH infusion, there was a 23% decrease in bone volume due to the increase in marrow space, a 93% increase in the number of osteoclasts and 136% increment in the osteoclastic resorption surface. Electron microscopic examination of the osteoclasts in the first tissue sample showed no evidence of ruffled borders, while in the second biopsy, numerous cytoplasmic processes indicative of resorptive activity were visible at the matrix-cell interface. It is proposed that, in our patient, the osteopetrotic phenotype is the consequence of an abnormality in the interaction between PTH and osteoclasts that may be related to the synthesis of a physiologically "defective" PTH.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974819     DOI: 10.1016/0221-8747(81)90033-3

Source DB:  PubMed          Journal:  Metab Bone Dis Relat Res        ISSN: 0221-8747


  7 in total

1.  Osteoclast abnormalities in idiopathic osteopetrosis. Reference to the ultrastructural histochemistry study.

Authors:  P van Tran; A Dryll; J Lansaman; B Naveau; R Treve; L Miravet; A Ryckewaert
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

2.  Skeletal resistance to 1,25-dihydroxyvitamin D3 in osteopetrotic rats.

Authors:  F F Safadi; D C Hermey; S N Popoff; M F Seifert
Journal:  Endocrine       Date:  1999-12       Impact factor: 3.633

3.  Juvenile osteopetrosis: effects on blood and bone of prednisone and a low calcium, high phosphate diet.

Authors:  L M Dorantes; A M Mejia; S Dorantes
Journal:  Arch Dis Child       Date:  1986-07       Impact factor: 3.791

4.  Failure of calcitriol treatment in a patient with malignant osteopetrosis.

Authors:  E M van Lie Peters; D C Aronson; V Everts; L J Dooren
Journal:  Eur J Pediatr       Date:  1993-10       Impact factor: 3.183

5.  Variable osteoclast appearance in human infantile osteopetrosis.

Authors:  F Shapiro; L L Key; C Anast
Journal:  Calcif Tissue Int       Date:  1988-08       Impact factor: 4.333

6.  Characterization and management of hypercalcemia following transplantation for osteopetrosis.

Authors:  C Martinez; L E Polgreen; T E DeFor; T Kivisto; A Petryk; J Tolar; P J Orchard
Journal:  Bone Marrow Transplant       Date:  2009-10-05       Impact factor: 5.483

7.  Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis.

Authors:  Anna Taranta; Silvia Migliaccio; Irene Recchia; Maurizio Caniglia; Matteo Luciani; Giulio De Rossi; Carlo Dionisi-Vici; Rita M Pinto; Paola Francalanci; Renata Boldrini; Edoardo Lanino; Giorgio Dini; Giuseppe Morreale; Stuart H Ralston; Anna Villa; Paolo Vezzoni; Domenico Del Principe; Flaminia Cassiani; Giuseppe Palumbo; Anna Teti
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.